
|Videos|March 4, 2019
Highlighting Immunotherapy Progress in Bladder Cancer
Author(s)Shilpa Gupta, MD
Shilpa Gupta, MD, discusses the progress over the last few years in bladder cancer.
Advertisement
Shilpa Gupta, MD, genitourinary oncologist at the University of Minnesota, discusses the progress made with immunotherapy in bladder cancer over the last few years.
There has been many advances in terms of immunotherapy in this patient population, and many trials are combining chemotherapy with these agents in the hopes of improving overall survival and gaining more durable responses, says Gupta. Later this year, we will learn more about these data as they read out.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































